Citi Downgrades PTC Therapeutics (PTCT) to Neutral
Tweet
Share
E-mail
Get Alerts PTCT Hot Sheet
Price: $84.43 -0.09%
Rating Summary:
17 Buy, 6 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 20 | New: 25
Rating Summary:
17 Buy, 6 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 20 | New: 25
Join SI Premium – FREE
Citi analyst Joel Beatty downgraded PTC Therapeutics (NASDAQ: PTCT) from Buy to Neutral with a price target of $67.00 (from $67.00).
For an analyst ratings summary and ratings history on PTC Therapeutics click here. For more ratings news on PTC Therapeutics click here.
Shares of PTC Therapeutics closed at $53.89 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- JPMorgan Downgrades Supreme Industries (SI:IN) to Neutral
- Stephens Downgrades Bio-Techne Corp. (TECH) to Equal Weight
- Northland Downgrades Quantum Corp. (QMCO) to Market Perform
Create E-mail Alert Related Categories
DowngradesRelated Entities
CitiSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
